GSK Looks To Cross PD-1 Gap And Leap To Next-Generation IO Backbone
This article was originally published in Scrip
GlaxoSmithKline PLC isn't letting the fact that it doesn’t have a PD-1/L1 inhibitor get its immuno-oncology R&D efforts down. Instead, the company is focusing immuno-oncology research on next-generation checkpoint modulators, including the OX40 agonist antibody GSK3174998 and first-in-class ICOS agonist antibody GSK3359609, the company said during an R&D day in New York City Nov. 3.
You may also be interested in...
GlaxoSmithKline's new CEO is assembling a "dream team" to rebuild the big pharma's R&D pipeline with an emphasis on building in oncology. Walmsley outlined her strategy at J.P. Morgan, while Oncology Therapy Area Head Axel Hoos provided more details in an interview.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.
Regeneron CEO Len Schleifer and President George Yancopoulos talked at the Stat Summit about launching their COVID-19 antibody cocktail and planning for the next pandemic.